Bisphosphonate treatment in the oim mouse model alters bone modeling during growth

Journal of Biomechanics

Volumn 41, Issue 16, 2008, Pages 3371-3376

  Rao, S H ^a   Evans, K D ^b   Oberbauer, A M ^b   Martin, R B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bisphosphonate; Bone; Oim mouse; Osteogenesis imperfecta; Pamidronate

Indexed keywords

BISPHOSPHONATE; BISPHOSPHONATES; BONE GROWTHS; BONE MATERIALS; LONG BONES; MOMENT OF INERTIAS; MOUSE MODELS; OIM MOUSE; OSTEOGENESIS IMPERFECTA; PAMIDRONATE; QUALITY OF LIVES; TYPE I COLLAGENS;

BONE;

BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE FRAGILITY; BONE GROWTH; BONE REMODELING; BONE STRENGTH; CONTROLLED STUDY; DIAPHYSIS; FEMALE; FEMUR; MALE; METAPHYSIS; MOUSE; NONHUMAN; OSTEOGENESIS IMPERFECTA; OSTEOLYSIS; PERIOSTEUM; PRIORITY JOURNAL;

ANIMALS; BONE DEVELOPMENT; BONE REMODELING; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FEMUR; MALE; MICE; ORGAN SIZE; OSTEOGENESIS IMPERFECTA; TREATMENT OUTCOME;

EID: 56549131344     PISSN: 00219290     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbiomech.2008.09.028     Document Type: Article

References (42)

1. Alman B., and Frasca P. Fracture failure mechanisms in patients with osteogenesis imperfecta. Journal of Orthopaedic Research 5 1 (1987) 139-143
2. Astrom E., and Soderhall S. Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Archives of Disease in Childhood 86 5 (2002) 356-364
3. Bagi C.M., Hanson N., et al. The use of micro-CT to evaluate cortical bone geometry and strength in nude rats: correlation with mechanical testing, pQCT and DXA. Bone 38 1 (2006) 136-144
4. Bembi B., Parma A., et al. Intravenous pamidronate treatment in osteogenesis imperfecta. Journal of Pediatrics 131 (1997) 622-625
5. Burr D.B., and Hooser M. Alterations to the en bloc basic fuchsin staining protocol for the demonstration of microdamage produced in vivo. Bone 17 4 (1995) 431-433
6. Byers P.H. Osteogenesis imperfecta. In: Royce P.M., and Steinmann B. (Eds). Connective Tissue and Its Heritable Disorders (1993), Wiley-Liss, New York 317-350
7. Camacho N.P., Hou L., et al. The material basis for reduced mechanical properties in oim mice bones. Journal of Bone and Mineral Research 14 2 (1999) 264-272
8. Camacho N.P., Raggio C.L., et al. A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta. Calcified Tissue International 69 (2001) 94-101
9. Chevrel G., and Meunier P.J. Osteogenesis imperfecta: lifelong management is imperative and feasible. Joint Bone Spine 68 2 (2001) 125-129
10. Dunford J.E., Thompson K., et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. JPET 296 2 (2001) 235-242
11. Fratzl P., Paris O., et al. Bone mineralization in an osteogenesis imperfecta mouse model studied by small-angle X-ray scattering. Journal of Clinical Investigation 97 2 (1996) 396-402
12. Frith J.C., and Rogers M.J. Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro. Journal of Bone and Mineral Research 18 2 (2003) 204-212
13. Garn, S., 1970. The Earlier Gain and the Later Loss of Cortical Bone in Nutritional Perspective.Charles C. Thomas, Springfield.
14. Glorieux F.H., Bishop N.J., et al. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. The New England Journal of Medicine 339 14 (1998) 947-952
15. Land C., Rauch F., et al. Cyclical intravenous pamidronate treatment affects metaphyseal modeling in growing patients with osteogenesis imperfecta. Journal of Bone and Mineral Research 21 3 (2006) 374-379
16. Landman O.J., Hamdy N.A., et al. Skeletal metabolism in patients with osteoporosis after discontiuation of long term treatment with oral pamidronate. Journal of Clinical Endocrinology and Metabolism 80 12 (1995) 3465-3468
17. Landsmeer-Beker E.A., Massa G.G., et al. Treatment of osteogenesis imperfecta with the bisphosphonate olpadronate (dimethylaminohydrosypropylidene bisphosphonate). European Journal of Pediatrics 156 (1997) 792-794
18. Licata A.A. Discovery, clinical development, and therapeutic uses of bisphosphonates. The Annals of Pharmacotherapy 39 4 (2005) 668-677
19. Lin J.H. Bisphosphonates: a review of their pharmacokinetic properties. Bone 18 2 (1996) 75-85
20. Lin J.H., Chen I.W., et al. Effects of dose, sex, and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate, in rats. Drug Metabolism and Disposition 20 4 (1992) 473-478
21. Lindsay R. Modeling the benefits of pamidronate in children with osteogenesis imperfecta. Journal of Clinical Investigation 110 9 (2002) 1239-1241
22. Lopez M.J., and Markel M.D. Bending Tests of Bone. In: An Y., and Draughn R. (Eds). Mechanical Testing of Bone and the Bone-Implant Interface (2000), CRC Press, Boca Raton 207-217 (Chapter 12)
23. Martin R.B. Size, structure, and gender: lessons about fracture risk. Journal of Musculoskeletal and Neuronal Interactions 2 3 (2002) 209-211
24. McBride D.J., Shapiro J.R., et al. Bone geometry and strength measurements in aging mice with the oim mutation. Calcified Tissue International 62 (1998) 172-176
25. McCarthy E.A., Raggio C.L., et al. Alendronate treatment for infants with osteogenesis imperfecta: demonstration of efficacy in a mouse model. Pediatric Research 52 5 (2002) 660-670
26. Miller E., Delos D., et al. Abnormal mineral-matrix interactions are a significant contributor to fragility in oim/oim bone. Calcified Tissue International 81 (2007) 206-214
27. Misof B.M., Roschger P., et al. Differential effects of alendronate treatment on bone from growing osteogenesis imperfecta and wild-type mouse. Bone 36 1 (2005) 150-158
28. Paterson C.R. Osteogenesis imperfecta and other heritable disorders of bone. Baillieres Clinical Endocrinology and Metabolism 11 1 (1997) 195-213
29. Plotkin H., Rauch F., et al. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. The Journal of Clinical Endocrinology and Metabolism 85 5 (2000) 1846-1850
30. Pomp D., and Murray J.D. Single day detection of transgenic mice by PCR of toe-clips. Mouse Genome 89 (1991) 279
31. Primorac D., Rowe D.W., et al. Osteogenesis imperfecta at the beginning of bone and joint decade. Croatian Medical Journal 42 4 (2001) 393-415
32. Rauch F., Plotkin H., et al. Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism. Journal of Clinical Endocrinology and Metabolism 88 3 (2003) 986-992
33. Rauch F., Cornibert S., et al. Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta. Bone 40 4 (2007) 821-827
34. Rogers M.J. From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates. Calcified Tissue International 75 6 (2004) 451-461
35. Saban J., Zussman M.A., et al. Heterozygous oim mice exhibit a mild form of osteogenesis imperfecta. Bone 19 6 (1996) 575-579
36. Sato M., Grasser W., et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. The Journal of Clinical Investigation 88 6 (1991) 2095-2105
37. Shoenfeld Y. Osteogenesis imperfecta. Review of the literature with presentation of 29 cases. American Journal of Diseases of Children 129 6 (1975) 679-687
38. Sillence D.O., Senn A., et al. Genetic heterogeneity in osteogenesis imperfecta. Journal of Medical Genetics 16 (1979) 101-116
39. Sims N.A., Brennan K., et al. Perinatal testosterone surge is required for normal adult bone size but not for normal bone remodeling. American Journal of Physiology-Endocrinology and Metabolism 290 3 (2006) E456-E462
40. Syed F., and Khosla S. Mechanisms of sex steriod effects on bone. Biochemical and Biophysical Research Communications 328 (2005) 688-696
41. Van Beek E.R., Cohen L.H., et al. Differentiation the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone 33 (2003) 805-811
42. Wang X., Bank R.A., et al. Effect of collagen denaturation on the toughness of bone. Clinical Orthopaedics 371 (2000) 228-239